Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor

por Jang, Seong, Strickland, Bill, Finis, Lynda, Kooijman, Jeffrey J., Melis, Janneke J. T. M., Zaman, Guido J. R., Van Tornout, Jan
Publicado 2023

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with a...

por Ciuleanu, Tudor-Eliade, Ahmed, Samreen, Kim, Joo-Hang, Mezger, Jörg, Park, Keunchil, Thomas, Michael, Chen, Jihong, Poondru, Srinivasu, VanTornout, Jan M, Whitcomb, Debbie, Blackhall, Fiona
Publicado 2017

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

por Noel, Marcus S., Kim, Semmie, Hartley, Marion L., Wong, Steve, Picozzi, Vincent J., Staszewski, Harry, Kim, Dae Won, Van Tornout, Jan M., Philip, Philip Agop, Chung, Vincent, Ocean, Allyson J., Wang‐Gillam, Andrea
Publicado 2022

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

por Mateo, Joaquin, Olmos, David, Dumez, Herlinde, Poondru, Srinivasu, Samberg, Nancy L, Barr, Sharon, Van Tornout, Jan M, Jie, Fei, Sandhu, Shahneen, Tan, Daniel S, Moreno, Victor, LoRusso, Patricia M, Kaye, Stan B, Schöffski, Patrick
Publicado 2016

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

por Hanna, Glenn J., Ahn, Myung-Ju, Muzaffar, Jameel, Keam, Bhumsuk, Bowles, Daniel W., Wong, Deborah J., Ho, Alan L., Kim, Sung-Bae, Worden, Francis, Yun, Tak, Meng, Xianzhang, Van Tornout, Jan M., Conlan, Maureen G., Kang, Hyunseok
Publicado 2023